BRCA1 and neoplasm: In breast cancer cells, mutations in BRCA1 and BRCA2 differentially modulate the tumor-immune microenvironment, which may be partially due to distinct mutational and copy number profiles, resulting in differential responses to checkpoint blockade immunotherapy [49].